TRIMTECH Therapeutics
To add a bio or update company history, please click update information.
News from TRIMTECH Therapeutics
TRIMTECH Therapeutics
23 Jun 2026
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
TRIMTECH Therapeutics
5 Mar 2025
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
TRIMTECH Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £35m
- trimtechtherapeutics.com
- Update Information
More venture news
- 29 Jul 2026
QureightQureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences - 7 Jul 2026
Healome TherapeuticsHealome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease
SeedLife Sciences - 6 Jul 2026
Revolver TherapeuticsRevolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
EquityLife Sciences
